Search - tctmd.com

Displaying 1 - 13 of 13

Sort: Relevancy | Date

News Industry News

Corvia Medical Announces Randomization of First Patient in the RESPONDER-HF Confirmatory Trial

December 06, 2022

News Features

A Hole in the Heart for HFpEF? Setbacks, Progress for Interatrial Shunts

Shelley Wood

July 07, 2022

Presentation TVT 2022

Exercise PVR, A Key Predictor of Benefit of Atrial Shunt Therapy in HFpEF?

Presenter: Sanjiv Shah

June 10, 2022

Presentation TVT 2022

What (Else) Have We Learned From REDUCE-LAP II?

Presenter: Sanjiv Shah

June 10, 2022

News Daily News ESC Heart Failure 2022

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

Shelley Wood

May 22, 2022

Presentation THT 2022

AXON Therapeutics

Presenter: Sanjiv J. Shah

February 02, 2022

News Industry News

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia Atrial Shunt in Large Segment of Heart Failure Patients

February 02, 2022

News Conference News THT 2022

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Shelley Wood

February 01, 2022

Presentation THT 2022

Physiological Phenotyping

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

REDUCE LAP-HF II Randomized Study of the Corvia Atrial Shunt -- Primary Results

Presenter: Sanjiv Shah

February 01, 2022

Presentation THT 2022

CON - PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Presenter: Sanjiv Shah

February 01, 2022

Advertisement

Corvia Medical Announces Randomization of First Patient in the RESPONDER-HF Confirmatory Trial

A Hole in the Heart for HFpEF? Setbacks, Progress for Interatrial Shunts

Exercise PVR, A Key Predictor of Benefit of Atrial Shunt Therapy in HFpEF?

What (Else) Have We Learned From REDUCE-LAP II?

SERENADE: No Benefit, Possible Harm With Macitentan in HFpEF and PAH

AXON Therapeutics

Landmark REDUCE LAP-HF II Trial Demonstrates Clinical Benefit of Corvia Atrial Shunt in Large Segment of Heart Failure Patients

REDUCE LAP-HF II: Atrial Shunt Device Comes Up Short in HFpEF

Physiological Phenotyping

Current status of the REBALANCE-HF US FDA randomized feasibility clinical trial in HFpEF

Long-term follow-up on FIH experience using the Satera Ablation System in HFpEF and HFrEF

REDUCE LAP-HF II Randomized Study of the Corvia Atrial Shunt -- Primary Results

CON - PRO - LA decompression is unnecessary in the era of SGLT2 inhibitors and ARNI's!

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content